Search results
Results from the WOW.Com Content Network
For men over 64 with prostate cancer limited to the pelvis, using fewer, larger doses of radiation (hypofractionation) results in similar overall survival rates. [28] The risk of dying from prostate cancer or having acute bladder side effects may be similar to that of longer radiation treatment. [28]
The Prostate Health Index (PHI) is a PSA-based blood test for early prostate cancer screening. It may be used to determine when a biopsy is needed. [32] [46] Prostate cancer antigen 3 is a urine test that detects the overexpression of the PCA3 gene, an indicator of prostate cancer. [32] [46] [47] [44]
Prostate cancer is a major topic of ongoing research. From 2016–2020, over $1.26 billion was invested in prostate cancer research, representing around 5% of global cancer research funds. [123] This places prostate cancer 10th among 18 common cancer types in funding per cancer death, and 9th in funding per disability-adjusted life year lost. [124]
Here’s an overview of what PSA test results mean and the next steps if your levels are high. ... Prostate cancer is usually graded between 6 and 10, Dr. Levin says. ... Grade Groups range from 1 ...
Whether you’re one of the 30 million men who have (ED) or not, you’ve almost certainly heard of Viagra. Maybe you even know about other ED medications, like Levitra or Stendra or Cialis, too.
Chemical structure of sildenafil (Viagra), the prototypical PDE5 inhibitor. A phosphodiesterase type 5 inhibitor (PDE5 inhibitor) is a vasodilating drug that works by blocking the degradative action of cGMP-specific phosphodiesterase type 5 (PDE5) on cyclic GMP in the smooth muscle cells lining the blood vessels supplying various tissues.
The test also significantly reduced unnecessary biopsies for individuals with indolent, low-grade prostate cancer. The results are exciting, but questions remain as to whether the test would ...
The prostate is a gland that is found under the rectum and below the bladder in the male reproductive system. [5] Five randomized controlled trials were conducted to determine whether prostate cancer screening reduces mortality associated with prostate cancer where 341,342 participants within the age range of 45–80 years were included in the ...